Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Biotechnology

Healthcare
$162.86 -0.45%

-$0.71 today

Market cap
$16.48B
Beta
0.40
P/E (TTM)
23.8
EPS (TTM)
$6.65
52W Low $122.14High $169.57

Volume 1.60M

Average 1.18M

NBIX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Neurocrine Biosciences, Inc.NASDAQ: NBIX

Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026

Selling, general & admin grows in line with its trailing trend

Q3 FY2026 selling, general & admin of $366.3M rose 25.6% year over year, ahead of the +24.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 16.7% from the prior quarter. Over 3 fiscal years it compounded at +15.4% a year.

Context

  • Selling, general & admin amounted to 40.4% of revenue in FY2025, down 2.3 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 18 analysts of $1.85B (+60.2%) for the fiscal year ending Dec 2026, a step up from the +14.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$366.3M-16.7% QoQ
Last fiscal yearDec 2025
$1.16B+14.8% YoY
LTMSep 2026
$1.43B+24.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.6%+68.2%+42.5 pp
1 year+14.8%+60.2%+45.4 pp
3-year CAGR+15.4%+26.5%+11.1 pp
5-year CAGR+17.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
1.16B USD
Year-over-year change
+14.8%
4-year CAGR
+18.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How NBIX compares with its peers on the latest reported figures

  • NBIX's LTM Sep 2026 selling, general & admin of $1.43B is the 2nd highest of the 10 companies compared; the peer median is $256.23M.
  • Its year-over-year change of +24.9% is the 6th highest of 10, against a peer median of +35.6%.
  • Selling, general & admin amounts to 38.5% of revenue for NBIX, versus a peer median of 79.7%.
NBIX Competitors Peer median
Selling, General & Admin for NBIX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JAZZJazz Pharmaceuticals plcLTM Sep 2026$1.56B -12.2%+8.5%33.0%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$1.43B +24.9%+15.4%38.5%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$712.67M +55.0%+53.0%91.8%
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026$646.09M +23.5%+14.1%53.7%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$560.88M +68.6%+8.8%67.5%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$256.23M +54.0%+20.4%117.7%
BHVNBiohaven Ltd.LTM Jun 2026$99.69M -4.4%-6.7%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$55.57M -17.1%+24.5%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$34.27M +37.9%+181.0%171.4%
GHRSGH Research PLCLTM Mar 2026$23.07M +35.6%+29.0%—
Peer median (excluding NBIX) $256.23M+35.6%+20.4%79.7%

Competitors are the stored peer set for NBIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.13B1.49B1.89B2.36B2.86B
Cost of Revenue14.3M23.2M39.7M34M52.1M
Gross Profit1.12B1.47B1.85B2.32B2.81B
Gross Margin98.7%98.4%97.9%98.6%98.2%
Research & Development328.1M463.8M565M731.1M1.02B
Selling, General & Admin583.3M752.7M887.6M1.01B1.16B
Operating Expenses1.02B1.22B1.6B1.75B2.19B
Depreciation & Amortization10.9M15.6M21.3M27.1M30.1M
EBITDA138.1M236.6M416.1M639.7M666.6M
EBITDA Margin12.2%15.9%22.0%27.2%23.3%
Operating Income102.5M249M250.9M570.5M619.1M
Operating Margin9.0%16.7%13.3%24.2%21.6%
Interest Income011.2M091M90.3M
Interest Expense25.8M7.1M4.6M126.6M0
Other Income / Expenses(1.1M)(35.1M)81.2M(84.5M)86.3M
Income Before Tax101.4M213.9M332.1M486M705.4M
Pre-Tax Margin8.9%14.4%17.6%20.6%24.7%
Income Tax Expense11.8M59.4M82.4M144.7M226.8M
Net Income89.6M154.5M249.7M341.3M478.6M
Net Margin7.9%10.4%13.2%14.5%16.7%
EPS (Basic)0.951.612.563.404.81
EPS (Diluted)0.921.562.473.294.67
Weighted Avg Shares94.6M95.8M97.7M100.4M99.5M
Weighted Avg Shares (Diluted)97.9M98.9M101M103.7M102.5M

Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Intrinsic Alpha fair value

Locked

Current Price

$162.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.